Cardiac AI: Who Owns Post-Market Vulnerability Risk?

The way we think about medical device vulnerabilities is doing a 180-degree turn. We’ve moved past worrying about a single piece of hardware failing on its own and are now dealing with the messy reality of interconnected software. For healthcare AI, this isn’t just a small adjustment. It blows up the whole concept of pre-clearance assessment, morphing it into a continuous post-deployment duty. This leads to the one question that should be keeping medtech leaders up at night: when a patient’s well-being relies on immediately patching a vulnerability across a whole network of devices, who actually owns that surveillance job?

The Shifting Sands of Medical Device Vulnerability

If you look at Medcrypt’s multi-year data, which they lay out in “The 2025 Medical Cybersecurity Field,” you see a clear pattern in manufacturer-reported vulnerabilities since 2019. The problems have moved away from hardware-specific bugs and are now almost entirely about software talking to other software. This technical detail signals a deep re-orientation of risk, especially for AI devices. Where old devices were mostly islands, a single bug in one component can now spread across a hospital’s network, putting patients at risk in real time. Medcrypt 2025 Medical Cybersecurity Field report For AI health tools, this change means a one-and-done risk assessment before you go to market is no longer good enough. Software, and especially AI/ML models that are supposed to learn over time, needs someone watching it constantly for security and safety issues. Think about something like algorithmic drift, that’s a functional vulnerability that won’t even show up until after deployment, and you’ve got to be monitoring for it or patients could get hurt.

From Hardware Isolation to Software Interconnectivity

This move from hardware bugs to software network issues really shows how complicated modern medical devices have become. With SaMD (Software as a Medical Device) and connected AI solutions everywhere, the attack surface isn’t just bigger, it’s enormous. A bug that used to be stuck inside one machine can now be used to attack an entire network of them, putting a huge number of patients in jeopardy all at once. An attack surface this big demands proactive vulnerability management. You can’t just sit back and wait. The manufacturer vulnerability reports that Medcrypt’s analysis centers on are one side of this post-deployment responsibility. It’s about finding, flagging, and fixing risks that come from how software behaves in the wild, not just from flaws in the original code. This challenge is technical, organizational, and regulatory all at once.

Cerebral’s Recorded Post-Market Surveillance Standard

With vulnerabilities changing so fast, Post-Market Surveillance (PMS) is becoming a key safety standard. Cerebral’s recorded materials are clear on this: they call out PMS as a core safety standard, defining it as a duty that starts the moment a device is deployed and requires you to keep collecting evidence long after you get FDA clearance. That definition fits the needs of a connected software world to a T. PMS is a continuous, evidence-generating process, not just some regulatory box you tick. For AI-powered medical devices, PMS is even more important. It means you’re looking for typical cybersecurity holes and also hunting for things like algorithmic drift, corrupted data, and hidden biases that could cause an AI to spit out bad medical advice or completely miss a diagnosis. Continuously monitoring and reacting to these emergent risks is absolutely essential for AI patient safety. So the real question is, how do we turn this documented duty into actual, accountable ownership when everything is connected?

Who Owns Vulnerability Surveillance Once Devices Stay Connected?

So let’s get to the point. Once all medical devices are talking to each other through software, who is actually responsible for Post-Market Surveillance of vulnerabilities? We see the problem clearly enough. Medcrypt’s analysis shows the risk is pooling in this interconnected software, which by definition is a post-deployment problem. And Cerebral’s recorded standard for Post-Market Surveillance tells us exactly what kind of duty is needed to handle it. The problem isn’t that we don’t know what to do. It’s that we haven’t assigned who does it. The safety of AI in patient care hangs on this answer. A vulnerability reported once devices are connected means there’s already a live threat, one that could cause an algorithm to miss a drug interaction, undertriage a heart attack, or fail to spot a stroke. Manufacturer reporting is a start, but a full PMS framework has to spell out a clear chain of command for finding, judging, and fixing these risks. That means having solid protocols for data sharing, incident response, and continuous risk assessment across all connected devices and software. NIST guidance on supply chain risk management for medical devices Sure, current regulations like the HHS guidance on HIPAA and NIST SP 800-66r2 talk a lot about security and privacy. HHS HIPAA guidance But assigning ownership for nonstop vulnerability watching in a world full of connected, AI-driven devices is still a messy, unsolved problem. When you read something like Medcrypt’s “The 2025 Medical Cybersecurity Field,” don’t just nod at the trend, ask who, specifically, is going to be held accountable. Without a clear owner, the danger to patients in these connected systems will only grow, leaving a huge hole where a solid framework for clinically validated AI should be.